Rare Blood Clot Risk Higher From Coronavirus Than Vaccine, Says UK Study

Compared to the current COVID-19 vaccines being administered, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher.

The risk of rare blood clotting following the COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza, according to a new University of Oxford study published on Thursday. The research found that the rare blood clotting known as Cerebral Venous Thrombosis (CVT) is more common after COVID-19 than in any of the comparison groups, with 30 per cent of these cases occurring in the under 30s. Compared to the current COVID-19 vaccines being administered, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher. The study follows reports of possible links between the Oxford/AstraZeneca vaccine and rare cases of CVT, which are undergoing deeper investigations by the medicines regulators even as the jabs have been ruled as safe and effective.